

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Relaquine 35 mg/ml Oral Gel for Horses (AT, DE, DK, FR, NL, UK(NI))
Plegicil vet 35 mg/ml Oral Gel for Horses (NO, SE)
Prohydol 35 mg/ml Oral Gel for Horses (BE)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Acepromazine	35.00 mg
(as Acepromazine maleate)	47.50 mg)

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Methyl parahydroxybenzoate (E218)	0.65 mg
Propyl parahydroxybenzoate	0.35 mg
Sodium acetate trihydrate	
Sodium cyclamate (E952)	
Hydroxyethylcellulose	
Glycerol (E422)	
Purified water	

Clear yellow gel for oral administration.

3. CLINICAL INFORMATION

3.1 Target species

Horses.

3.2 Indications for use for each target species

For sedation of horses.

3.3 Contraindications

Do not use in cases of post-traumatic shock or hypovolaemia.
Do not use in animals in a state of severe emotional excitation.
Do not use in animals with epilepsy.
Do not use in pregnant or lactating mares.
Do not use in animals with heart failure.
Do not use in animals with haematological disorders/coagulopathies.
Do not use in animals suffering from hypothermia.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in neonates.

3.4 Special warnings

Sedation lasts for approximately six hours, although the actual time and depth of sedation are very dependent on the status of the individual animal.

Increasing the dosage above that recommended results in prolonged action and side effects but no greater sedation.

3.5 Special precautions for use

Special precautions for safe use in the target species:

In stallions, the lowest dose range is indicated to minimise prolapse of the penis.

The veterinary medicinal product should be used with caution and with reduced dosage in the case of cardiac or hepatic disease or in debilitated, hypovolemic or anaemic animals.

Acepromazine has negligible analgesic effects. Painful activities should be avoided when handling tranquillized animals.

Tranquillized horses should be kept in a calm place and sensorial stimuli should be avoided as far as possible.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands and exposed skin thoroughly after use.

Persons with sensitive skin or in continuous contact with the veterinary medicinal product are advised to wear impermeable gloves.

Avoid eye contact. In case of accidental eye contact, rinse the eye for 15 minutes with clean water and consult a physician if irritation persists.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician but, DO NOT DRIVE as sedation can occur.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Horse:

Rare (1 to 10 animals / 10,000 animals treated):	Excitation ¹
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Low blood pressure ² , Hypothermia ³ , Hyperthermia ³ Decreased red blood cell count ⁴ , Decreased haemoglobin ⁴ , Low platelet count ⁴ , Leucopenia ⁴ Infertility ⁵ , Penile prolapse ⁶ , Paraphimosis ⁷ , Priapism ⁷ Aggression ⁸ , Generalized central nervous system stimulation ⁸ Prolapse of the nictitating membrane

¹ Paradoxical reaction

² Since acepromazine decreases sympathetic nervous system tone, a transient drop in blood pressure may occur after administration.

³ Inhibition of temperature regulation.

⁴ Transient.

⁵ Because it increases prolactin secretion, the administration of acepromazine may lead to disturbances in fertility.

⁶ Due to the relaxation of the retractor penis muscles. Retraction of the penis should be visible within two to three hours. If this does not take place, it is advised to contact a veterinary surgeon. Lack of retraction is of particular concern in breeding stallions.

⁷ Acepromazine has caused paraphimosis sometimes in sequel to priapism.

⁸ Contradictory clinical signs

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Acepromazine should not be used in pregnant or lactating mares.

Acepromazine has the potential to induce hypotension in newborns when administered as a premedication for caesarean section in the mare.

Please see also Section 3.6 relating to disturbances in fertility.

3.8 Interaction with other medicinal products and other forms of interaction

Acepromazine potentiates the action of centrally depressant drugs.

Simultaneous administration, or administration to horses recently treated with organophosphates should be avoided, since these molecules enhance the toxic effects of acepromazine. Since acepromazine decreases sympathetic nervous system tone, simultaneous treatment with blood pressure lowering products should not take place.

Antacids may cause a decrease in the gastrointestinal absorption of acepromazine after oral administration.

Opiates may enhance the hypotensive effects of acepromazine.

3.9 Administration routes and dosage

For oral administration.

Prefilled syringe

The veterinary medicinal product is contained within a 10 ml or 15 ml polyethylene syringe. The plunger has a locking ring which should be adjusted to provide the volume required in accordance with the dosage guidelines. 1.0 ml intervals are printed on the syringe plunger, but it is also possible to dose at 0.5 ml intervals.

Before first use of the syringe, turn the locking ring clockwise until aligned with the 0.0 ml mark (side of the ring facing the barrel). Turn the locking ring anti-clockwise will move the ring backwards. Turn the locking ring backwards until the left side of the locking ring lines up with the volume of the oral gel to be administered.

Place the syringe in the animal's mouth and expel the required dose into the cheek pouch. The gel may also be mixed with food.

Glass bottle

The veterinary medicinal product is filled into 10, 15, 20, 30 and 50 ml glass bottles with CRC closure and supplied with a 5 ml syringe with a dose graduation allowing accurate dosing of 0.1 or 0.2 ml. Withdraw the appropriate dose from the bottle using the supplied syringe. The syringe is brought into the animal's mouth and the appropriate dose is expelled into the animal's cheek. The gel may also be mixed with food.

Amount(s) to be administered

Moderate sedation: 0.15 mg acepromazine per kg bodyweight

Dosage guidelines:

Bodyweight (kg)	200	300	400	450	500	600
Dose (ml)	1.0	1.5	1.5	2.0	2.5	2.5

The above dosage information is provided as a guideline. The dose may be varied to administer between 0.5 and 1.5 times the above recommendation depending on the level of sedation required, i.e. for mild sedation, administer half the recommended dose and for deeper sedation, administer 1½ times the recommended dose.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdosage results in an earlier onset of the sedative symptoms and in a prolonged effect. Toxic effects are ataxia, hypotension, hypothermia and central nervous system (extrapyramidal) effects. **Noradrenaline, but not adrenaline, can be used to counteract the cardiovascular effects.**

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not authorised for use in horses intended for human consumption.
Not authorised for use in animals producing milk for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QN05AA04

4.2 Pharmacodynamics

Acepromazine is a phenothiazine derivative. This group of molecules belongs to the neuroleptics: they depress the central nervous system and exert associated effects on the autonomic system. These effects are due to their interference with different neurotransmitter receptors (dopaminergic, adrenergic) and to their interference with hypothalamic performance. The sedative activity starts within 15 to 30 minutes of treatment and lasts for 6 -7 hours.

The desired effects observed after treatment with acepromazine include a general tranquillizing effect, anti-emetic effect and a slight anti-histaminic effect. There is no analgesic action. The neuroleptic effects are variable between individual animals.

4.3 Pharmacokinetics

Acepromazine is partly absorbed from the gastrointestinal tract. Plasma protein binding is high and it is extensively distributed throughout the body tissues. Plasma levels are usually low. Acepromazine is highly metabolised, with the urine as the main route of excretion.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

Shelf life after first opening the immediate packaging: 90 days

5.3 Special precautions for storage

Do not store above 25 °C.

Protect from frost.

Protect from light.

After use, replace cap on syringe. Keep the broached syringe in the original carton and store in a dry place.

5.4 Nature and composition of immediate packaging

Prefilled syringes:

Container: White, high-density polyethylene syringe barrel and a white, low-density polyethylene syringe plunger closed with a white, high-density polyethylene, push-fit cap.

Or

White, linear low-density polyethylene syringe closed with a linear low-density polyethylene, push-fit cap.

Fill volume: 10 ml
15 ml

Dosing device: The veterinary medicinal product is presented in an oral dosing syringe which is graduated at 1 ml intervals.

Glass bottles

Container: Amber Type III glass bottles of 10, 15, 20, 30 and 50 ml, fitted with syringe adaptors and HDPE/LDPE CRC closures containing 9 ml, 14 ml, 18 ml, 28 ml and 48 ml product, respectively.

Dosing device: The veterinary medicinal product is presented with an oral dosing syringe of 5 ml which is graduated at 0.1 or 0.2 ml intervals.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Floris Holding BV

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation:

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

MM/YYYY

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

SYRINGE CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Relaquine 35 mg/ml Oral Gel for Horses (AT, DE, DK, FR, NL, UK(NI))
Plegicil vet 35 mg/ml Oral Gel for Horses (NO, SE)
Prohydol 35 mg/ml Oral Gel for Horses (BE)

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains 35 mg acepromazine (as acepromazine maleate 47.50 mg)

3. PACKAGE SIZE

10 ml syringe
15 ml syringe

4. TARGET SPECIES

Horses

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

For oral administration.

7. WITHDRAWAL PERIODS

Not authorised for use in horses intended for human consumption. Not authorised for use in animals producing milk for human consumption.

8. EXPIRY DATE

Exp {month/year}
Once broached, use within 90 days.

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C. Protect from frost. Protect from light.
After use, replace cap on syringe. Keep the broached syringe in the original carton and store in a dry place.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

User warning:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or product label to the physician, but DO NOT DRIVE as sedation can occur.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Floris Holding BV

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

BOTTLE CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Relaquine 35 mg/ml Oral Gel for Horses (AT, DE, DK, FR, NL, UK(NI))
Plegicil vet 35 mg/ml Oral Gel for Horses (NO, SE)
Prohydol 35 mg/ml Oral Gel for Horses (BE)

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains 35 mg acepromazine (as acepromazine maleate 47.50 mg)

3. PACKAGE SIZE

9 ml bottle
14 ml bottle
18 ml bottle
28 ml bottle
48 ml bottle

4. TARGET SPECIES

Horses

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

For oral administration.

7. WITHDRAWAL PERIODS

Not authorised for use in horses intended for human consumption. Not authorised for use in animals producing milk for human consumption.

8. EXPIRY DATE

Exp {month/year}
Once broached, use within 90 days.

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C. Protect from frost. Protect from light.

After use, replace cap on syringe. Keep the broached syringe in the original carton and store in a dry place.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

User warning:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or product label to the physician, but **DO NOT DRIVE** as sedation can occur.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Floris Holding BV

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
SYRINGE LABEL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Relaquine (AT, DE, DK, FR, NL, UK(NI))
Plegicil vet (NO, SE)
Prohydol (BE)

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

35 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}
Once broached use within 90 days.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

BOTTLE LABEL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Relaquine (AT, DE, DK, FR, NL, UK(NI))

Plegicil vet (NO, SE)

Prohydol (BE)

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

35 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 90 days.

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Relaquine 35 mg/ml Oral Gel for Horses (AT, DE, DK, FR, NL, UK(NI))

Plegicil vet 35 mg/ml Oral Gel for Horses (NO, SE)

Prohydol 35 mg/ml Oral Gel for Horses (BE)

2. Composition

Each ml contains 35 mg acepromazine (as acepromazine maleate 47.50 mg) as active substance, 0.65 mg methyl parahydroxybenzoate (E218) and 0.35 mg propyl parahydroxybenzoate as preservatives.

Clear yellow gel for oral administration.

3. Target species

Horses.

4. Indications for use

For sedation of horses.

5. Contraindications

Do not use in cases of post-traumatic shock or hypovolaemia.

Do not use in animals in a state of severe emotional excitation.

Do not use in animals with epilepsy.

Do not use in pregnant or lactating mares.

Do not use in animals with heart failure.

Do not use in animals with haematological disorders/coagulopathies.

Do not use in animals suffering from hypothermia.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in neonates.

6. Special warnings

Special warnings:

Sedation lasts for approximately six hours, although the actual time and depth of sedation are very dependent on the status of the individual animal.

Increasing the dosage above that recommended results in prolonged action and side effects but no greater sedation.

Special precautions for safe use in the target species:

In stallions the lowest dose range is indicated to minimise prolapse of the penis.

The veterinary medicinal product should be used with caution and with reduced dosage in the case of cardiac or hepatic disease or in debilitated, hypovolemic or anaemic animals.

Acepromazine has negligible analgesic effects. Painful activities should be avoided when handling tranquilized animals.

Tranquillized horses should be kept in a calm place and sensorial stimuli should be avoided as far as possible.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands and exposed skin thoroughly after use.

Persons with sensitive skin or in continuous contact with the veterinary medicinal product are advised to wear impermeable gloves.

Avoid eye contact. In case of accidental eye contact, rinse the eye for 15 minutes with clean water and consult a physician if irritation persists. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or product label to the physician, but DO NOT DRIVE as sedation can occur.

Pregnancy and lactation:

Acepromazine should not be used in pregnant or lactating mares.

Acepromazine has the potential to induce hypotension in newborns when administered as a premedication for caesarean section in the mare.

Please see also Section Adverse events relating to disturbances in fertility.

Interaction with other medicinal products and other forms of interaction:

Acepromazine potentiates the action of centrally depressant drugs.

Simultaneous administration, or administration to horses recently treated with organophosphates should be avoided, since these molecules enhance the toxic effects of acepromazine.

Since acepromazine decreases sympathetic nervous system tone, simultaneous treatment with blood pressure lowering products should not take place.

Antacids may cause a decrease in the gastrointestinal absorption of acepromazine after oral administration.

Opiates may enhance the hypotensive effect of acepromazine.

Overdose:

Overdosage results in an earlier onset of the sedative symptoms and in a prolonged effect. Toxic effects are ataxia, hypotension, hypothermia and central nervous system (extrapyramidal) effects.

Noradrenaline, but not adrenaline, can be used to counteract the cardiovascular effects.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Horse:

Rare (1 to 10 animals / 10,000 animals treated):

Excitation¹

Very rare (<1 animal / 10,000 animals treated, including isolated reports):

Low blood pressure², Hypothermia³, Hyperthermia³, Decreased red blood cell count⁴, Decreased haemoglobin⁴, Low platelet count⁴, Leucopenia⁴ (low white blood cell count), Infertility⁵, Penile prolapse⁶, Paraphimosis⁷ (retracted foreskin, which cannot return into the normal position), Priapism⁷ (prolonged erection of the penis), Aggression⁸, Generalized central nervous system stimulation⁸, Prolapse of the nictitating membrane.

¹ Paradoxical reaction.

² Since acepromazine decreases sympathetic nervous system tone, a transient drop in blood pressure may occur after administration.

³ Inhibition of temperature regulation.

⁴ Transient.

⁵ Because it increases prolactin secretion, the administration of acepromazine may lead to disturbances in fertility.

⁶ Due to the relaxation of the retractor penis muscles. Retraction of the penis should be visible within two to three hours. If this does not take place, it is advised to contact a veterinary surgeon. Lack of retraction is of particular concern in breeding stallions.

⁷ Acepromazine has caused paraphimosis sometimes in sequel to priapism.

⁸ Contradictory clinical signs.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

Moderate sedation of horses: 0.15 mg acepromazine per kg bodyweight

Dosage guidelines

Bodyweight (kg)	200	300	400	450	500	600
Dose (ml)	1.0	1.5	1.5	2.0	2.5	2.5

The above dosage information is provided as a guideline. The dose may be varied to administer between 0.5 and 1.5 times the above recommendation according to the level of sedation required, i.e. for mild sedation, administer half the recommended dose and for deeper sedation, administer 1.5 times the recommended dose.

9. Advice on correct administration

For oral administration.

Prefilled syringe

The veterinary medicinal product is contained within a 10 ml or 15 ml polyethylene syringe. The plunger has a locking ring which should be adjusted to provide the volume required in accordance with the dosage guidelines. 1.0 ml intervals are printed on the syringe plunger, but it is also possible to dose at 0.5 ml intervals.

Before first use of the syringe, turn the locking ring clockwise until aligned with the 0.0 ml mark (side of the ring facing the barrel). Turn the locking ring anti-clockwise will move the ring backwards. Turn the locking ring backwards until the left side of the locking ring lines up with the volume of the oral gel to be administered.

Place the syringe in the animal's mouth and expel the required dose into the cheek pouch. The gel may also be mixed with food.

Glass bottle

The veterinary medicinal product is filled into 10, 15, 20, 30 and 50 ml glass bottles with CRC closure and supplied with a 5 ml syringe with a dose graduation of 0.1 or 0.2 ml. Withdraw the appropriate dose from the bottle using the supplied syringe. The syringe is brought into the animal's mouth and the appropriate dose is expelled into the animal's cheek.

The gel may also be mixed with food.

10. Withdrawal periods

Not authorised for use in horses intended for human consumption.

Not authorised for use in animals producing milk for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 25 °C. Protect from frost. Protect from light.

After use, replace cap on syringe. Keep the broached syringe in the original carton and store in a dry place.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the syringe: 90 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Polyethylene adjustable syringe containing 10 ml or 15 ml gel.

Amber Type III glass bottles containing 9, 14, 18, 28 and 48 ml gel.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

MM/YYYY

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Floris Holding BV
Kempenlandstraat 33
5.262 GK Vught
The Netherlands
+31(0)73 656 76 47
pharmacovigilance@florispharma.com

Manufacturer responsible for batch release:

Floris Veterinaire Produkten B.V.
Kempenlandstraat 33
5262 GK Vught
The Netherlands

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

--